These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 17502830

  • 1. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N.
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [Abstract] [Full Text] [Related]

  • 2. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population.
    Cáliz R, del Amo J, Balsa A, Blanco F, Silva L, Sanmarti R, Martínez FG, Collado MD, Ramirez Mdel C, Tejedor D, Artieda M, Pascual-Salcedo D, Oreiro N, Andreu JL, Graell E, Simon L, Martínez A, Mulero J.
    Scand J Rheumatol; 2012 Feb; 41(1):10-4. PubMed ID: 22044028
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
    Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ.
    Arthritis Rheum; 2006 Apr; 54(4):1087-95. PubMed ID: 16572443
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene.
    Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, Abou Atta I, Mevorach D, Friedman G, Ben-Yehuda A.
    Ann Rheum Dis; 2004 Oct; 63(10):1227-31. PubMed ID: 15361376
    [Abstract] [Full Text] [Related]

  • 5. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
    Soejima M, Kawaguchi Y, Hara M, Kamatani N.
    J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
    [No Abstract] [Full Text] [Related]

  • 6. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 7. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N.
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [Abstract] [Full Text] [Related]

  • 8. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
    Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N.
    J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
    [Abstract] [Full Text] [Related]

  • 9. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.
    Schmeling H, Biber D, Heins S, Horneff G.
    J Rheumatol; 2005 Sep; 32(9):1832-6. PubMed ID: 16142884
    [Abstract] [Full Text] [Related]

  • 10. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A, Kamatani N.
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract] [Full Text] [Related]

  • 11. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases.
    Mena JP, Salazar-Páramo M, González-López L, Gámez-Nava JI, Sandoval-Ramirez L, Sánchez JD, Figuera LE, Muñoz-Valle FJ, Vazquez del Mercado M, Dávalos IP.
    Pharmacogenomics J; 2011 Aug; 11(4):287-91. PubMed ID: 20514079
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
    Taniguchi A, Urano W, Tanaka E, Akama H, Yamanaka H, Kamatani N.
    Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
    [Abstract] [Full Text] [Related]

  • 13. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation.
    Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R.
    Indian J Med Res; 2006 Nov; 124(5):521-6. PubMed ID: 17213520
    [Abstract] [Full Text] [Related]

  • 14. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
    Soukup T, Dosedel M, Pavek P, Nekvindova J, Barvik I, Bubancova I, Bradna P, Kubena AA, Carazo AF, Veleta T, Vlcek J.
    Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
    [Abstract] [Full Text] [Related]

  • 15. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF.
    N Engl J Med; 1996 May 16; 334(20):1287-91. PubMed ID: 8609945
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T.
    J Rheumatol; 2008 Apr 16; 35(4):550-2. PubMed ID: 18398948
    [No Abstract] [Full Text] [Related]

  • 17. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 16; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 18. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms.
    Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, Barton A.
    Pharmacogenomics J; 2013 Apr 16; 13(2):137-47. PubMed ID: 21931346
    [Abstract] [Full Text] [Related]

  • 19. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y, Abou Atta I, Rubinow A, Orbach H, Levartovsky D, Aamar S, Arbel O, Dresner-Pollak R, Friedman G, Ben-Yehuda A.
    J Rheumatol; 2007 Aug 16; 34(8):1664-9. PubMed ID: 17611986
    [Abstract] [Full Text] [Related]

  • 20. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
    J Rheumatol; 2008 Jun 16; 35(6):979-85. PubMed ID: 18412314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.